Regeneron Has Strong Showing, But No REGEN-COV Sales Expected In First Half

Analysts Highlight Potential Growth Opportunities

Dupixent sales grew by more than 50% as Eylea and REGEN-COV also drove sales growth, though the antiviral advantage will vanish due to the FDA restricting its use.

4th quarter computer key on key board
Regeneron reported its fourth quarter and full year 2021 sales on 4 February • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. capped off 2021 squeezing one last bit of juice from its COVID-19 antibody cocktail, which along with Eylea (aflibercept) and Sanofi-partnered Dupixent (dupilumab) helped generate much of the company’s sales growth – but the company anticipates no revenue in the near term from the Roche Holding AG-partnered cocktail, REGEN-COV/Ronapreve (casirivimab/imdevimab) due to lack of efficacy against Omicron. Instead, management is playing up the potential for long-term sales growth in its pipeline.

On 4 February, the company reported fourth quarter 2021 revenues of $5bn and full year revenues of $16.1bn, respectively increases...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By 

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By 

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Business

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By 

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By 

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.